Brian H Ramnaraign, M.D.
Assistant Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
ramnaraign85@ufl.edu
About Brian H Ramnaraign
Brian Ramnaraign, MD is an assistant professor of medicine in the division of hematology and oncology at the University of Florida College of Medicine.
Dr. Ramnaraign attended the University of Toronto for his undergraduate studies where he was awarded an Honors Bachelors of Science degree with a specialization in molecular genetics and microbiology. This was followed by attending St. George’s University for his medical training where he was awarded the degree of Doctor of Medicine and graduated cum laude.
His internal medicine residency was completed at SUNY Downstate in Brooklyn, NY where Dr. Ramnaraign had the opportunity to participate in rotations at Memorial Sloan Kettering in Manhattan. After residency he obtained a fellowship in geriatrics at the University of Pennsylvania in Philadelphia, PA.
Dr. Ramnaraign completed his hematology and oncology fellowship here at the University of Florida and upon completion stayed on as faculty. His wife is also here at the University of Florida and is training to be a pediatric oncologist.
His expertise and research interests are in the fields of genitourinary cancers, gastrointestinal cancers and neuroendocrine cancers. He is interested in the role of targeted therapies and immunotherapies in providing personalized treatments to individuals with advanced cancers.
Accomplishments
FLASCO Travel Award Winner
2017
·
UF, College of Medicine
Runner Up – Research Day Award
2015
·
SUNY Downstate Department of Medicine
Physician Recognition Award
2014
·
American Medical Association
Dean’s List
2008-2012
·
St. George’s University
Teaching Profile
Courses Taught
2020
PAS5010 Intro to Medicine 1
Board Certifications
-
Geriatric MedicineAmerican Board of Internal Medicine
-
HematologyAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
-
Medical OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
- Hematology and Oncology
Areas of Interest
- Bladder Cancer
- Colorectal cancer
- Gastrointestinal cancer
- Kidney cancer
- Pancreatic cancer
- Prostate Cancer
Research Profile
Google Scholar: https://scholar.google.com/citations?user=OBsb4P4AAAAJ&hl=en
Open Researcher and Contributor ID (ORCID)
0000-0003-4051-4551
Areas of Interest
- Cancer Immunotherapy
- Esophageal cancer
- Neuroendocrine Tumors
- Pancreatic Cancer Biology
- Prostate Cancer
- Targeted Cancer Therapy
Publications
2024
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
Clinical Genitourinary Cancer.
22(1):67-75
[DOI] 10.1016/j.clgc.2023.09.002.
2023
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
Future Oncology.
19(27):1841-1851
[DOI] 10.2217/fon-2023-0256.
[PMID] 37753702.
2023
Addendum: Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.
Oncotarget.
14
[DOI] 10.18632/oncotarget.28491.
[PMID] 38085073.
2023
Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis.
Journal of hepatocellular carcinoma.
10:1129-1141
[DOI] 10.2147/JHC.S417273.
[PMID] 37489126.
2023
Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.
Oncotarget.
14:351-357
[DOI] 10.18632/oncotarget.28406.
[PMID] 37068159.
2023
Pneumocystis jirovecii pneumonia in a patient treated with trastuzumab-deruxtecan.
BMJ case reports.
16(2)
[DOI] 10.1136/bcr-2022-253647.
[PMID] 36805876.
2023
Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study
Cancers.
15(20)
[DOI] 10.3390/cancers15205055.
[PMID] 37894422.
2023
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
The Oncologist.
28(5):392-401
[DOI] 10.1093/oncolo/oyac279.
[PMID] 36806966.
2023
Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
29(5):1206-1217
[DOI] 10.1177/10781552231171079.
[PMID] 37097888.
2022
Administration of Immune Checkpoint Inhibitors Near the End of Life
JCO Oncology Practice.
18(6):e849-e856
[DOI] 10.1200/op.21.00689.
2022
Advanced Hepatocellular Carcinoma in Adults Without Cirrhosis: A Single-Institution Retrospective Review.
Journal of hepatocellular carcinoma.
9:1299-1307
[DOI] 10.2147/JHC.S384438.
[PMID] 36567797.
2022
Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial
Future Oncology.
18(34):3815-3822
[DOI] 10.2217/fon-2022-0392.
2022
Clinical Updates for Colon Cancer Care in 2022.
Clinical colorectal cancer.
21(3):198-203
[DOI] 10.1016/j.clcc.2022.05.006.
[PMID] 35729033.
2022
Predicting Complete Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Cancers.
15(1)
[DOI] 10.3390/cancers15010168.
[PMID] 36612164.
2022
Tivozanib for the treatment of advanced renal cell carcinoma.
Expert opinion on pharmacotherapy.
23(10):1135-1142
[DOI] 10.1080/14656566.2022.2102419.
[PMID] 35848061.
2021
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
The oncologist.
26(5):362-e724
[DOI] 10.1002/onco.13689.
[PMID] 33512054.
2021
Immunotherapy Management in Special Cancer Patient Populations
JCO Oncology Practice.
17(5):240-245
[DOI] 10.1200/op.20.00996.
2021
Primary neuroendocrine tumours of the heart: case report and literature review.
BMJ case reports.
14(6)
[DOI] 10.1136/bcr-2021-242517.
[PMID] 34116995.
2021
Reply to A.R. Khaki et al
JCO Oncology Practice.
17(9):584-586
[DOI] 10.1200/op.21.00484.
2021
Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
JAMA network open.
4(11)
[DOI] 10.1001/jamanetworkopen.2021.33474.
[PMID] 34812849.
2020
Germline BRCA1 mutated esophageal squamous cell carcinoma.
Rare tumors.
12
[DOI] 10.1177/2036361320972218.
[PMID] 33224455.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics.
108(3):557-565
[DOI] 10.1002/cpt.1912.
[PMID] 32460360.
2015
An analysis of the relationship between severe iron deficiency anemia and thrombocytopenia.
Annals of hematology.
94(3):535-7
[DOI] 10.1007/s00277-014-2199-5.
[PMID] 25190032.
Grants
Dec 2022
ACTIVE
Blood plasma and buffy coat samples including corresponding clinical information in de-identified form for each patient sample
Role: Co-Project Director/Principal Investigator
Funding: BILLIONTOONE
Dec 2022
ACTIVE
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via BAYER HEALTHCARE PHARMACEUTICALS
May 2022
ACTIVE
MAIN-CAV: PHASE III RANDOMIZED TRIAL OF MAINTENANCE CABOZANTINIB AND AVELUMAB VS MAINTENANCE AVELUMAB AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH METASTATIC UROTHELIAL CANCER
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Nov 2021
ACTIVE
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Oct 2021
ACTIVE
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Jul 2021
ACTIVE
Comparative Effectiveness Research for Neuroendocrine Tumors (CER-NET)
Role: Other
Funding: UNIV OF IOWA
via PATIENT-CENTERED OUTCOMES RES INST
Aug 2020
ACTIVE
A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
Role: Principal Investigator
Funding: RADIATION THERAPY ONCOLOGY GROUP FOU
Aug 2018
– Jul 2023
A PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS
Role: Principal Investigator
Funding: ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
via NATL INST OF HLTH NCI
Education
Fellowship, Hematology – Oncology
2016-2019
·
University of Florida
Fellowship, Geriatric Medicine
2015-2016
·
University of Pennsylvania
Internal Medicine
2012-2015
·
State University of New York Health Science Center at Brooklyn
Doctor of Medicine, Internal Medicine
2008-2012
·
St. George’s University School of Medicine
Honors Bachelors of Science, Molecular Genetics
2003-2007
·
University of Toronto
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- ramnaraign85@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100278
GAINESVILLE FL 32610